S100A12 Suppresses Pro-inflammatory, but Not Pro-Thrombotic Functions of Serum Amyloid A

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Chung, Yuen Ming ^a   Goyette, Jesse ^a,b   Tedla, Nicodemus ^a   Hsu, Kenneth ^a   Geczy, Carolyn L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATASE; PROTEIN S100A12; REACTIVE OXYGEN METABOLITE; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM TRANSPORT; CELL PROTECTION; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; HUMAN; HUMAN CELL; MACROPHAGE ACTIVATION; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTHROMBOTIC FUNCTION; RNA STABILITY; THROMBOSIS;

CALCIUM; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEUKOCYTES, MONONUCLEAR; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; S100 PROTEINS; SERUM AMYLOID A PROTEIN; THROMBOPLASTIN;

EID: 84876523060     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062372     Document Type: Article

References (101)

1. Urieli-Shoval S, Linke RP, Matzner Y, (2000) Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hema 7: 64-69.
2. Urieli-Shoval S, Cohen P, Eisenberg S, Matzner Y, (1998) Widespread expression of serum amyloid A in histologically normal human tissues: predominant localization to the epithelium. J Histochem Cytochem 46: 1377-1384.
3. Meek RL, Urieli-Shoval S, Benditt EP, (1994) Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc Natl Acad Sci U S A 91: 3186-3190.
4. Yamada T, Wada A, Itoh K, Igari J, (2000) Serum amyloid A secretion from monocytic leukaemia cell line THP-1 and cultured human peripheral monocytes. Scand J Immunol 52: 7-12.
5. Miwata H, Yamada T, Okada M, Kudo T, Kimura H, et al. (1993) Serum amyloid A protein in acute viral infections. Arch Dis Child 68: 210-214.
6. Kumon Y, Suehiro T, Itahara T, Ikeda Y, Hashimoto K, (1994) Serum amyloid A protein in patients with non-insulin-dependent diabetes mellitus. Clin Biochem 27: 469-473.
7. Ridker PM, Hennekens CH, Buring JE, Rifai N, (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342: 836-843.
8. Cunnane G, Grehan S, Geoghegan S, McCormack C, Shields D, et al. (2000) Serum amyloid A in the assessment of early inflammatory arthritis. J Rheumatol 27: 58-63.
9. Malle E, Sodin-Semrl S, Kovacevic A, (2009) Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci 66: 9-26.
10. Eriksen N, Benditt EP, (1980) Isolation and characterization of the amyloid-related apoprotein (SAA) from human high density lipoprotein. Proc Natl Acad Sci U S A 77: 6860-6864.
11. Hoffman JS, Benditt EP, (1982) Secretion of serum amyloid protein and assembly of serum amyloid protein-rich high density lipoprotein in primary mouse hepatocyte culture. J Biol Chem 257: 10518-10522.
12. O'Hara R, Murphy EP, Whitehead AS, FitzGerald O, Bresnihan B, (2004) Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. Arthritis Rheum 50: 1788-1799.
13. Chung TF, Sipe JD, McKee A, Fine RE, Schreiber BM, et al. (2000) Serum amyloid A in Alzheimer's disease brain is predominantly localized to myelin sheaths and axonal membrane. Amyloid 7: 105-110.
14. Dong Z, Wu T, Qin W, An C, Wang Z, et al. (2011) Serum amyloid A directly accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. J Mol Med 17: 1357-1364.
15. Song C, Hsu K, Yamen E, Yan W, Fock J, et al. (2009) Serum amyloid A induction of cytokines in monocytes/macrophages and lymphocytes. Atherosclerosis 207: 374-383.
16. Cai H, Song C, Endoh I, Goyette J, Jessup W, et al. (2007) Serum amyloid A induces monocyte tissue factor. J Immunol 178: 1852-1860.
17. Wang X, Chai H, Wang Z, Lin PH, Yao Q, et al. (2008) Serum amyloid A induces endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol 295: 2399-2408.
18. Witting PK, Song C, Hsu K, Hua S, Parry SN, et al. (2011) The acute-phase protein serum amyloid A induces endothelial dysfunction that is inhibited by high-density lipoprotein. Free Radic Biol Med 51: 1390-1398.
19. Furlaneto CJ, Campa A, (2000) A novel function of serum amyloid A: a potent stimulus for the release of tumor necrosis factor-α, interleukin-1β, and interleukin-8 by human blood neutrophil. Biochem Biophys Res Commun 268: 405-408.
20. He R, Sang H, Ye RD, (2003) Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood 101: 1572-1581.
21. Ribeiro FP, Furlaneto CJ, Hatanaka E, Ribeiro WB, Souza GM, et al. (2003) mRNA expression and release of interleukin-8 induced by serum amyloid A in neutrophils and monocytes. Mediators Inflamm 12: 173-178.
22. Yavin EJ, Preciado-Patt L, Rosen O, Yaron M, Suessmuth RD, et al. (2000) Serum amyloid A-derived peptides, present in human rheumatic synovial fluids, induce the secretion of interferon-γ by human CD4+ T-lymphocytes. FEBS Lett 472: 259-262.
23. Badolato R, Wang JM, Murphy WJ, Lloyd AR, Michiel DF, et al. (1994) Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med 180: 203-209.
24. Olsson N, Siegbahn A, Nilsson G, (1999) Serum amyloid A induces chemotaxis of human mast cells by activating a pertussis toxin-sensitive signal transduction pathway. Biochem Biophys Res Commun 254: 143-146.
25. Okamoto H, Katagiri Y, Kiire A, Momohara S, Kamatani N, (2008) Serum amyloid A activates nuclear factor-kappaB in rheumatoid synovial fibroblasts through binding to receptor of advanced glycation end-products. J Rheumatol 35: 752-756.
26. Bozinovski S, Uddin M, Vlahos R, Thompson M, McQualter JL, et al. (2012) Serum amyloid A opposes lipoxin A(4) to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A 109: 935-940.
27. Lee HY, Kim SD, Shim JW, Lee SY, Lee H, et al. (2008) Serum amyloid A induces CCL2 production via formyl peptide receptor-like 1-mediated signaling in human monocytes. J Immunol 181: 4332-4339.
28. Liang TS, Wang JM, Murphy PM, Gao JL, (2000) Serum amyloid A is a chemotactic agonist at FPR2, a low-affinity N-formylpeptide receptor on mouse neutrophils. Biochem Biophys Res Commun 270: 331-335.
29. Zhao Y, Zhou S, Heng CK, (2007) Impact of serum amyloid A on tissue factor and tissue factor pathway inhibitor expression and activity in endothelial cells. Arterioscler Thromb Vasc Biol 27: 1645-1650.
30. Cheng N, He R, Tian J, Ye PP, Ye RD, (2008) Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J Immunol. 181: 22-26.
31. He RL, Zhou J, Hanson CZ, Chen J, Cheng N, et al. (2009) Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2. Blood 113: 429-437.
32. Sandri S, Rodriguez D, Gomes E, Monteiro HP, Russo M, et al. (2008) Is serum amyloid A an endogenous TLR4 agonist? J Leukoc Biol 83: 1174-1180.
33. Baranova IN, Vishnyakova TG, Bocharov AV, Kurlander R, Chen Z, et al. (2005) Serum amyloid A binding to CLA-1 (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases. J Biol Chem 280: 8031-8040.
34. Cai L, de Beer MC, de Beer FC, van der Westhuyzen DR, (2005) Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake. J Biol Chem 280: 2954-2961.
35. Connolly M, Mullan RH, McCormick J, Matthews C, Sullivan O, et al. (2012) Acute-phase serum amyloid A regulates tumor necrosis factor alpha and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. Arthritis Rheum 64: 1035-1045.
36. Baranova IN, Bocharov AV, Vishnyakova TG, Kurlander R, Chen Z, et al. (2010) CD36 is a novel serum amyloid A (SAA) receptor mediating SAA binding and SAA-induced signaling in human and rodent cells. J Biol Chem 285: 8492-8506.
37. Foell D, Frosch M, Sorg C, Roth J, (2004) Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clinica Chimica Acta 344: 37-51.
38. Guignard F, Mauel J, Markert M, (1996) Phosphorylation of myeloid-related proteins MRP-14 and MRP-8 during human neutrophil activation. Eur J Biochem 241: 265-271.
39. Yang Z, Tao T, Raftery MJ, Youssef P, Di Girolamo N, et al. (2001) Proinflammatory properties of the human S100 protein S100A12. J Leukoc Biol 69: 986-994.
40. Hasegawa T, Kosaki A, Kimura T, Matsubara H, Mori Y, et al. (2003) The regulation of EN-RAGE (S100A12) gene expression in human THP-1 macrophages. Atherosclerosis 171: 211-218.
41. Goyette J, Yan WX, Yamen E, Chung YM, Lim SY, et al. (2009) Pleiotropic roles of S100A12 in coronary atherosclerotic plaque formation and rupture. J Immunol 183: 593-603.
42. Yang Z, Yan WX, Cai H, Tedla N, Armishaw C, et al. (2007) S100A12 provokes mast cell activation: a potential amplification pathway in asthma and innate immunity. J Allergy Clin Immunol 119: 106-114.
43. Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, et al. (2003) Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 52: 847-853.
44. Leach ST, Yang Z, Messina I, Song C, Geczy CL, et al. (2007) Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol 42: 1321-1331.
45. Foell D, Roth J, (2004) Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 50: 3762-3771.
46. Foell D, Ichida F, Vogl T, Yu X, Chen R, et al. (2003) S100A12 (EN-RAGE) in monitoring Kawasaki disease. Lancet 361: 1270-1272.
47. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, et al. (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97: 889-901.
48. Uhlar CM, Whitehead AS, (1999) Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 265: 501-523.
49. Yan WX, Armishaw C, Goyette J, Yang Z, Cai H, et al. (2008) Mast cell and monocyte recruitment by S100A12 and its hinge domain. J Biol Chem 283: 13035-13043.
50. Hofmann Bowman MA, Heydemann A, Gawdzik J, Shilling RA, Camoretti-Mercado B, (2011) Transgenic expression of human S100A12 induces structural airway abnormalities and limited lung inflammation in a mouse model of allergic inflammation. Clin Exp Allergy 41: 878-889.
51. Bjorkman L, Karlsson J, Karlsson A, Rabiet MJ, Boulay F, et al. (2008) Serum amyloid A mediates human neutrophil production of reactive oxygen species through a receptor independent of formyl peptide receptor like-1. J Leukoc Biol 83: 245-253.
52. Hatanaka E, Pereira Ribeiro F, Campa A, (2003) The acute phase protein serum amyloid A primes neutrophils. FEMS Immunol Med Microbiol 38: 81-84.
53. McCormick MM, Rahimi F, Bobryshev YV, Gaus K, Zreiqat H, et al. (2005) S100A8 and S100A9 in human arterial wall: implications for atherogenesis. J Biol Chem 280: 41521-41529.
54. Garner B, Li W, Roberg K, Brunk UT, (1997) On the cytoprotective role of ferritin in macrophages and its ability to enhance lysosomal stability. Free Radic Res 27: 487-500.
55. Hsu K, Passey RJ, Endoh Y, Rahimi F, Youssef P, et al. (2005) Regulation of S100A8 by glucocorticoids. J Immunol 174: 2318-2326.
56. Song C, Shen Y, Yamen E, Hsu K, Yan W, et al. (2009) Serum amyloid A may potentiate prothrombotic and proinflammatory events in acute coronary syndromes. Atherosclerosis 202: 596-604.
57. Shevchenko A, Wilm M, Vorm O, Mann M, (1996) Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68: 850-858.
58. Monick MM, Powers LS, Gross TJ, Flaherty DM, Barrett CW, et al. (2006) Active ERK contributes to protein translation by preventing JNK-dependent inhibition of protein Phosphatase 1. J Immunol 177: 1636-1645.
59. Bedard K, Krause KH, (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87: 245-313.
60. Ahmed H, Schott EJ, Gauthier JD, Vasta GR, (2003) Superoxide dismutases from the oyster parasite Perkinsus marinus: purification, biochemical characterization, and development of a plate microassay for activity. Anal Biochem 318: 132-141.
61. Walsh JD, Geczy CL, (1991) Discordant expression of tissue factor antigen and procoagulant activity on human monocytes activated with LPS and low dose cycloheximide. Thromb Haemost 66: 552-558.
62. Geczy CL, (1994) Cellular mechanisms for the activation of blood coagulation. Int Rev Cytol 152: 49-108.
63. Ravasi T, Hsu K, Goyette J, Schroder K, Yang Z, et al. (2004) Probing the S100 protein family through genomic and functional analysis. Genomics 84: 10-22.
64. van Lent PL, Grevers LC, Schelbergen R, Blom A, Geurts J, et al. (2010) S100A8 causes a shift toward expression of activatory Fcγ receptors on macrophages via toll-like receptor 4 and regulates Fcγ receptor expression in synovium during chronic experimental arthritis. Arthritis Rheum 62: 3353-3364.
65. Bjork P, Bjork A, Vogl T, Stenstrom M, Liberg D, et al. (2009) Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol 7: 800-812.
66. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, et al. (2007) Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 13: 1042-1049.
67. Sunahori K, Yamamura M, Yamana J, Takasugi K, Kawashima M, et al. (2006) The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis. Arthritis Res Ther 8: R69.
68. Beutler B, (2000) TLR4: central component of the sole mammalian LPS sensor. Curr Opin Immunol 12: 20-26.
69. Hiratsuka S, Watanabe A, Sakurai Y, Akashi-Takamura S, Ishibashi S, et al. (2008) The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol 10: 1349-1355.
70. Mishra JP, Mishra S, Gee K, Kumar A, (2005) Differential involvement of calmodulin-dependent protein kinase II-activated AP-1 and c-Jun N-terminal kinase-activated EGR-1 signaling pathways in tumor necrosis factor-α and lipopolysaccharide-induced CD44 expression in human monocytic cells. J Biol Chem 280: 26825-26837.
71. Lee HY, Kim MK, Park KS, Shin EH, Jo SH, et al. (2006) Serum amyloid A induces contrary immune responses via formyl peptide receptor-like 1 in human monocytes. Molecular Pharmacology 70: 241-248.
72. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, et al. (1994) The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 331: 417-424.
73. Tolle M, Huang T, Schuchardt M, Jankowski V, Prufer N, et al. (2012) High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc Res. 94: 154-162.
74. Jang SY, Shin YK, Lee HY, Park JY, Suh DJ, et al. (2012) Local production of serum amyloid a is implicated in the induction of macrophage chemoattractants in Schwann cells during wallerian degeneration of peripheral nerves. Glia 60: 1619-1628.
75. Ather JL, Ckless K, Martin R, Foley KL, Suratt BT, et al. (2011) Serum amyloid A activates the NLRP3 inflammasome and promotes Th17 allergic asthma in mice. J Immunol 187: 64-73.
76. Srikrishna G, Nayak J, Weigle B, Temme A, Foell D, et al. (2010) Carboxylated N-glycans on RAGE promote S100A12 binding and signaling. J Cell Biochem 110: 645-659.
77. Hoppmann S, Steinbach J, Pietzsch J, (2010) Scavenger receptors are associated with cellular interactions of S100A12 in vitro and in vivo. Int J Biochem Cell Biol 42: 651-661.
78. Hofmann Bowman MA, Gawdzik J, Bukhari U, Husain AN, Toth PT, et al. (2011) S100A12 in vascular smooth muscle accelerates vascular calcification in apolipoprotein E-null mice by activating an osteogenic gene regulatory program. Arterioscler Thromb Vasc Biol 31: 337-344.
79. Donato R, Sorci G, Riuzzi F, Arcuri C, Bianchi R, et al. (2009) S100B's double life: intracellular regulator and extracellular signal. Biochim Biophys Acta 1793: 1008-1022.
80. Goyette J, Geczy CL, (2011) Inflammation-associated S100 proteins: new mechanisms that regulate function. Amino Acids 41: 821-842.
81. Moroz OV, Blagova EV, Wilkinson AJ, Wilson KS, Bronstein IB, (2009) The crystal structures of human S100A12 in apo form and in complex with zinc: new insights into S100A12 oligomerisation. J Mol Biol 391: 536-551.
82. Wang L, Colon W, (2007) Effect of zinc, copper, and calcium on the structure and stability of serum amyloid A. Biochemistry. 46: 5562-5569.
83. Heizmann CW, Cox JA, (1998) New perspectives on S100 proteins: a multi-functional Ca2+-, Zn2+- and Cu2+-binding protein family. Biometals 11: 383-397.
84. Ohta S, Tanaka M, Sakakura K, Kawakami T, Aimoto S, et al. (2009) Defining lipid-binding regions of human serum amyloid A using its fragment peptides. Chem Phys Lipids 162: 62-68.
85. Andrassy M, Igwe J, Autschbach F, Volz C, Remppis A, et al. (2006) Posttranslationally modified proteins as mediators of sustained intestinal inflammation. Am J Pathol 169: 1223-1237.
86. Boyd JH, Kan B, Roberts H, Wang Y, Walley KR, (2008) S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ Res 102: 1239-1246.
87. Ghavami S, Rashedi I, Dattilo BM, Eshraghi M, Chazin WJ, et al. (2008) S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol 83: 1484-1492.
88. Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J, (2009) The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 86: 557-566.
89. Loser K, Vogl T, Voskort M, Lueken A, Kupas V, et al. (2010) The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med 16: 713-717.
90. Kerkhoff C, Sorg C, Tandon NN, Nacken W, (2001) Interaction of S100A8/S100A9-arachidonic acid complexes with the scavenger receptor CD36 may facilitate fatty acid uptake by endothelial cells. Biochemistry 40: 241-248.
91. Tak PP, Firestein GS, (2001) NF-κB: a key role in inflammatory diseases. J Clin Invest 107: 7-11.
92. Dokladda K, Green KA, Pan DA, Hardie DG, (2005) PD98059 and U0126 activate AMP-activated protein kinase by increasing the cellular AMP:ATP ratio and not via inhibition of the MAP kinase pathway. FEBS Lett 579: 236-240.
93. Cerioni L, Palomba L, Cantoni O, (2003) The Raf/MEK inhibitor PD98059 enhances ERK1/2 phosphorylation mediated by peroxynitrite via enforced mitochondrial formation of reactive oxygen species. FEBS Lett 547: 92-96.
94. Lorenz U, (2009) SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunol Rev 228: 342-359.
95. Camps M, Nichols A, Arkinstall S, (2000) Dual specificity phosphatases: a gene family for control of MAP kinase function. The FASEB J 14: 6-16.
96. Camps M, Nichols A, Gillieron C, Antonsson B, Muda M, et al. (1998) Catalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated protein kinase. Science 280: 1262-1265.
97. Pulido R, Zuniga A, Ullrich A, (1998) PTP-SL and STEP protein tyrosine phosphatases regulate the activation of the extracellular signal-regulated kinases ERK1 and ERK2 by association through a kinase interaction motif. EMBO J 17: 7337-7350.
98. Kamata H, Honda SI, Maeda S, Chang L, Hirata H, et al. (2005) Reactive oxygen species promote TNFα-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120: 649-661.
99. Traore K, Sharma R, Thimmulappa RK, Watson WH, Biswal S, et al. (2008) Redox-regulation of Erk1/2-directed phosphatase by reactive oxygen species: Role in signaling TPA-induced growth arrest in ML-1 cells. J Cell Physiol 216: 276-285.
100. Guyton KZ, Liu Y, Gorospe M, Xu Q, Holbrook NJ, (1996) Activation of mitogen-activated protein kinase by HO. J Biol Chem 271: 4138-4142.
101. Gatt ME, Urieli-Shoval S, Preciado-Patt L, Fridkin M, Calco S, et al. (1998) Effect of serum amyloid A on selected in vitro functions of isolated human neutrophils. J Lab Clin Med 132: 414-420.